19th MEET THE PROFESSOR

Advanced International Breast Cancer Course 2023
(AIBCC 2023)

Palazzo della Salute, Padova

21 | 22 September 2023

Presentation

Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynecologists and obstetrics
Medical oncologists
Pathologists

Radiologists
Radiation oncologists
Surgeons

Biologists
Pharmacists
Nurses

Scientific Program

Thursday, September 21st

10:00

Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly

10.30	Gene expression tools in early-stage HR+/HER2- breast cancer: when and which one? Gaia Griguolo
11.00	Biological insights of the immune system in breast cancer Maria Vittoria Dieci
11.30	DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones? Mafalda Oliveira
12.00	Tackling diversity in HER2-positive breast cancer: biological and clinical implications Tomas Pascual
12.30	Discussion
13.00	Lunch

SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
The changing relationship between locoregional recurrences and long-term outcomes

Chairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas

14.00	Mapping local and regional recurrences Orit Kaidar-person
14.30	The surgical perspective Eleftherios Mamounas
15.00	Deciphering the EBCTCG meta-analyses Philip Poortmans
15.30	Discussion
	Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly
16.00	Clinical case 1. Skin flap thickness for IBR Rosa Di Micco
16.15	Clinical case 2. When to resect/irradiate after systemic therapy for a recurrence Luca Visani
16.30	Clinical case 3: Local recurrence after DCIS Eleonora Ferrara
16.45	General discussion and concluding comments Jacek Jassem, Hesham Ahmed Gaballah Elghazaly
17.00	Adjourn
17.15	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023
17.30	Lecture of the Awardee
18.00	Adjourn

Friday, September 22nd

SESSION III – EARLY BREAST CANCER

Chairpersons: Alessandra Gennari, Valentina Guarneri

9.00	New therapeutic strategies in very young women: lights and shadows Angela Toss
9.20	Elderly patients: how old is too old in the contemporary scenario Laura Biganzoli
9.40	Neoadjuvant approach: rethinking the paradigm? Federica Miglietta
10.00	New ESMO Guidelines Sibylle Loibl
10.20	Discussion
10.50	Coffee break
	Multidisciplinary Tumor Board 2 – Early breast cancer Panelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Sibylle Loibl, Philip Poortmans
11.15	Genomic test in premenopausal patients Davide Massa
11.30	Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic risk Michele Bottosso
11.45	HER2+ pt1cN0: adjuvant or neoadjuvant? Ottavia Amato
12.00	General discussion and concluding comments Alessandra Gennari
12.30	Lunch

SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS

Chairpersons: Giuseppe Curigliano, Pierfranco Conte

13.30	HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance? Stephen Johnston
14.00	HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristics Sandra Swain M
14.30	Triple negative disease: something more than label indications to dictate treatment sequence? Hope Rugo
15.00	Discussion
	Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo, Sandra Swain
15.30	Visceral crisis Grazia Vernaci
16.00	Leptomeningeal metastases Cristina Falci
16.15	General discussion and concluding comments Carlo Alberto Giorgi
16.30	Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans